이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Lipum 관리

관리 기준 확인 1/4

Lipum's CEO는 Ola Sandborgh, Dec2023 에 임명되었습니다 의 임기는 1년 미만입니다. 는 SEK 322.49K 가치에 해당하는 회사 주식의 0.18% 직접 소유합니다. 322.49K. 경영진과 이사회의 평균 재임 기간은 각각 0.6 년과 3 년입니다.

주요 정보

Ola Sandborgh

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.2%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	3yrs

최근 관리 업데이트

Recent updates

CEO

Ola Sandborgh (58 yo)

less than a year

테뉴어

Mr. Ola Sandborgh serves as CEO at Lipum AB (publ) since December 01, 2023. He has experience from the pharmaceutical industry where he has worked in leading roles in different commercial, innovation and b...

리더십 팀

이름	위치	테뉴어	보상	소유권
Olle Hernell	Co-Founder & Director	no data	SEK 303.50k	1.61% SEK 3.0m
Marina Norberg	Chief Financial Officer	3.5yrs	SEK 553.50k	0.077% SEK 145.1k
Ola Sandborgh	Chief Executive Officer	less than a year	데이터 없음	0.18% SEK 333.7k
Susanne Lindquist	Co-Founder & Head of Research (CSO)	no data	데이터 없음	1.53% SEK 2.9m
Pernilla Abrahamsson	Chief Operating Officer	no data	데이터 없음	0.034% SEK 63.4k
Karin Franck-Larsson	C.M.O.	less than a year	데이터 없음	데이터 없음

0.7yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: LIPUM 의 관리팀은 경험 (평균 재직 기간 0.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Olle Hernell	Co-Founder & Director	no data	SEK 303.50k	1.61% SEK 3.0m
Gustav Kihlstrom	Independent Chairman of the Board	3.1yrs	데이터 없음	데이터 없음
Björn Löwenadler	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Carl-Johan Spak	Independent Director	1.2yrs	데이터 없음	0.017% SEK 31.2k
Anders Fasth	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lennart Lundberg	Member of Scientific Advisory Board	3yrs	데이터 없음	데이터 없음
Asa Hansdotter	Independent Director	3.1yrs	데이터 없음	데이터 없음
Kristian Sandberg	Independent Director	4.3yrs	데이터 없음	데이터 없음
Rikard Holmdahl	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Solbritt Dahlqvist	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Asa Magnusson	Director	less than a year	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

69.5yo

평균 연령

경험이 풍부한 이사회: LIPUM 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Lipum 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

High number of new directors

Lipum AB (publ) Announces Nomination Committee Appointments

Lipum AB (Publ) Appoints Ola Sandborgh as Chief Executive Officer, Effective from December 1, 2023

Lipum AB (Publ) Appoints Karin Franck-Larsson as CMO

Lipum Elects Carl-Johan Spak as New Board Member

Chief Executive Officer recently bought kr161k worth of stock

Recent updates

High number of new directors

Lipum AB (publ) Completes Multiple Dose Part of the Phase I Clinical Study

Lipum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 79.714945 million.

Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer

Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer

Forecast to breakeven in 2025

Lipum AB (publ) has filed a Follow-on Equity Offering.

Lipum AB (publ) has filed a Follow-on Equity Offering.

Lipum AB (publ) Reports Positive Interim Results from Clinical Phase 1 Study Showing that SOL-116 Reduces Plasma BSSL Levels in Healthy Subjects

Lipum AB (Publ) Receives Funding from Vinnova for an Eurostars Application

Lipum AB (publ) Announces Nomination Committee Appointments

Lipum AB (Publ) Appoints Ola Sandborgh as Chief Executive Officer, Effective from December 1, 2023

New major risk - Revenue and earnings growth

Lipum AB (Publ) Appoints Karin Franck-Larsson as CMO

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Lipum Elects Carl-Johan Spak as New Board Member

Chief Executive Officer recently bought kr161k worth of stock

Lipum AB (publ) Announces the Nomination Committee for the 2023 Annual General Meeting

Chief Executive Officer recently bought kr157k worth of stock

Lipum AB (Publ) Has Initiated A Phase 1 Clinical Study with Its Drug Candidate Sol-116

Lipum AB (publ) announced that it has received SEK 38.999963 million in funding from Flerie Invest AB

Lipum AB (publ) Gets Approval to Start Phase 1 Clinical Trial with Drug Candidate Sol-116

Lipum AB (publ) Appoints Helena Bergström as Chief Medical Officer

Lipum Reports Completion of GLP Toxicology- and Safety Program on the Candidate Drug (SOL-116)

Chief Executive Officer recently bought kr195k worth of stock

Lipum AB (Publ) Reports Gmp Production of Sol-116 Successful

Lipum Recruits Fredrik Seijsing as Scientist

Lipum AB (publ) Initiates GMP-Production for Clinical Trials

Lipum Is At the Final Step Before Clinical Phase

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령